The efficacy of the fecal occult blood test in colorectal cancer screening and evaluation with the literature: Two-year follow-up results of Rize province

Colakoglu, Muhammet Kadri; Pergel, Ahmet; DEMİRAL, GÖKHAN; AKDOĞAN, Remzi Adnan

The efficacy of the fecal occult blood test in colorectal cancer screening and evaluation with the literature: Two-year follow-up results of Rize province

Gökhan DEMİRAL, (Recep Tayyip Erdoğan Üniversitesi)

Muhammet Kadri ÇOLAKOĞLU, (Diğer)

Remzi Adnan AKDOĞAN, (Diğer)

Ahmet PERGEL (Diğer)

ACTA ONCOLOGICA TURCICA

2 0

Yıl: 2019 Cilt: 52 Sayı: 1 Sayfa Aralığı: 31 - 37 Metin Dili: İngilizce İndeks Tarihi: 04-12-2019

The efficacy of the fecal occult blood test in colorectal cancer screening and evaluation with the literature: Two-year follow-up results of Rize province

Öz:

INTRODUCTION: Early detection of colorectal cancer (CRC) reduces mortality and morbidity, and reducestreatment costs. It is possible to detect precancerous lesion or early stage tumor with screening programs. In thisstudy, the efficacy of the screening program was evaluated by examining colonoscopy findings andclinicopathological data of the patients who were taken to CRC screening program by Rize province CancerEarly Diagnosis Screening and Training Center and who were referred to our clinic with positive fecal occultblood test (FOBT) result.MATERIAL and METHODS: A total of 144 patients with positive FOBT (Wondfo One Step Fecal OccultBlood Test, Biotech Co.Ltd., Guangzhou, China) results were included in the study. Data were retrospectivelyreviewed from patient files. Demographic data of age and gender, endoscopic findings, anal physicalexamination findings, histopathological results, FOBT positivity rate, polyp + cancer detection rate and cancerdetection rates were evaluated.RESULTS: In this study, 74 of the patients (51.4%) were male and 70 (48.6%) were female and the mean agewas 60.1 (min 50-max 70). In 109 patients (75.7%) colonoscopic findings were normal. Hemorrhoid / analfissure was the cause of FOBT positivity in 31 patients (21.5 %). Colonoscopy positive patients were as follows;polyp in 21 patients (14.6 %), colonic diverticulum in 7 patients (4.9 %), nonspecific inflammation in 5 patients(3.5 %) and macroscopic tumor in 2 patients (1.4 %). FOBT positivity rate was 1.2 % (n: 144), polyp + cancerdetection rate was 0.19% (n: 23) and cancer detection rate was 0.017% (n: 2).DISCUSSION AND CONCLUSION: Immunochemical tests are the preferred choice for CRC in modernscreening program. In our study; the rates of participants, test positivity and malignancy were found to be quitelow. Promoting and encouraging public awareness of the need for FOBT and the correct implementation ofFOBTs will contribute to the success of screening programs.

Anahtar Kelime:

Konular: Tıbbi İnformatik Genel ve Dahili Tıp Temel Sağlık Hizmetleri Onkoloji Sağlık Bilimleri ve Hizmetleri

Kolorektal kanser taramada uygulanan gaytada gizli kan testinin etkinliği ve literatür eşliğinde değerlendirilmesi: Rize ili iki yıllık değerlendirme

Öz:

GİRİŞ ve AMAÇ: Kolorektal kanser (KRK)’ in erken evrede tespiti mortalite ve morbidite azalmasının yanı sıra tedavi maliyetlerini de düşürmektedir. Tarama programları ile prekanseröz lezyonu veya erken evre tümörü saptamak münkündür. Bu çalışmada Rize ili Kanser Erken Teşhis Tarama ve Eğitim Merkezince KRK tarama programına alınan ve gaitada gizli kan testi (GGKT) pozitif saptanarak merkezimize yönlendirilen hastaların kolonoskopi bulguları ve klinikopatolojik verileri incelenerek tarama programının etkinliği değerlendirilmiştir. YÖNTEM ve GEREÇLER: GGKT sonucu pozitif saptanan 144 hasta çalışmaya dahil edildi. Veriler hasta dosyalarından retrospektif olarak tarandı. Çalışma kapsamında hastaların yaş, cinsiyet gibi demografik verileri ile endoskopide saptanan bulgular, anal fizik muayene bulgusu, histopatolojik sonuçlar, GGKT pozitiflik oranı, polip + kanser saptanma oranı ve kanser saptanma oranları tespit edildi. BULGULAR: Çalışmada hastaların 74’ ü (% 51.4) erkek, 70’ i (% 48.6) kadın ve yaş ortalaması 60.1 (min 50- max 70) idi. Toplamda 109 hastada (% 75.7) kolonoskopik bulgular normal idi. 31 hastada (% 21.5) GGKT pozitifliğinin sebebi hemoroid/anal fissür idi. Kolonoskopisi pozitif olanlardan 21 hastada (% 14.6) polip, 7 hastada (% 4.9) kolon divertikülü, 5 hastada (% 3.5) nonspesifik inflamasyon ve 2 hastada (% 1.4) makroskopik tümör saptandı. GGKT pozitiflik oranı % 1.2 (n: 144), polip + kanser saptanma oranı % 0.19 (n: 23) ve kanser saptanma oranı % 0.017 (n: 2) idi. TARTIŞMA ve SONUÇ: İmmünokimyasal testler modern toplum tarama programında KRK için tercih edilen seçenektir. Çalışmamızda katılımcı sayısı, test pozitifliği ve malignite tespit oranları oldukça düşük saptanmıştır. Toplumun GGKT gerekliliği konusunda bilinçlendirilerek teşvik edilmesi ve GGKT’ lerin doğru uygulanması tarama programlarının başarıya ulaşmasına katkı sağlayacaktır.

Anahtar Kelime:

Konular: Tıbbi İnformatik Genel ve Dahili Tıp Temel Sağlık Hizmetleri Onkoloji Sağlık Bilimleri ve Hizmetleri

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Cancer Fact sheet February 2018. World Health Organization. http://www.who.int/en/newsroom/fact-sheets/detail/cancer Erişim Tarihi: 05.06.2018.
TÜİK. Ölüm Nedeni İstatistikleri, 2015. http://www.tuik.gov.tr/PreHaberBultenleri.do?id=2 1526.
https://hsgm.saglik.gov.tr/depo/birimler/ kanserdb/istatistik/TurkiyeKanserIstatistikleri 2015.pdf.
Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology 2010; 38: 2029-43.
Wei EK, Giovannucci E, Wu K. Comparison of risk factors for colon and rectal cancer. Int J Cancer 2004; 108: 433-42.
Burt RW, DiSario JA, Cannon-Albright L. Genetics of colon cancer: impact of inheritance on colon cancer risk. Annu Rev Med 1995; 46: 371-9.
Tözün N, Şimşek H, Özkan H, Şimşek İ, Gören A, editörler. Kolorektal Polipler ve Polipozis Sendromları. Klinik Gastoenteroloji ve Hepatoloji. Medikal ve Nobel Yayıncılık, 2007: 963-70.
Dolar E. Editör. Kolorektal Tümörler. Nobel ve Güneş Yayınları. 2005: 400-8.
https://hsgm.saglik.gov.tr/depo/birimler/ kanserdb/yayinlar/raporlar/kolorektal.pdf.
GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012. http://globocan.iarc.fr/Default.aspx
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–917.
Çakmur H, Anuk T, Önder T, Güven H, Köksal N. Kuzey-Doğu Anadolu Bölgesinde Görülen Kolorektal Kanserlerin Özellikleri. Turk J Colorectal Dis 2015; 25: 21-7.
Özkan ÖF, Kaya Ü, Güner A, Cevizci S, Özkul F, Sezer C, Reis E. Bir eğitim ve araştırma hastanesinde kolorektal kanser hastalarının demografik dağılımı ve hastalık özellikleri. Pam Tıp Derg 2012; 5: 132-5.
Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009; 101: 1412–22.
Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, et al. A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Making 2011; 31:530–9.
Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut 2015; 64: 1637-49.
Sung JJ, Ng SC, Chan FK, et al. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut 2015; 64:121–32.
Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103:1541–9.
Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. US Preventive Services Task Force. JAMA 2016; 315: 2564-75.
Kahi CJ, Imperiale TF, Juliar BE, Rex DK. Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin Gastroenterol Hepatol 2009; 7: 770-5.
Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009; 150: 1-8.
Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug U. Protection from right- and left sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst 2010; 102: 89-95.
Kolorektal Kanser Taraması ve Teşhisinde Avrupa Birliği Kalite Rehberi, Editorler: N. Segnan, J. Patnick, L. von Karsa, Çeviri Editörleri: Keskinkılıç B, Gültekin M, Karaca AS, Öztürk C, Hacıkamiloğlu E, Boztaş G, Turan H, Karaca M. 1. Baskı, Ankara, Ozyurt Matbaacılık, 2014.
Mayir B, Ensari CB, Durhan A, Çöpelci Y. Kolorektal Kanser Tarama Amaçlı Yapılan Gaytada Gizli Kan Testi Pozitif Saptanan Hastalarda Kolonoskopi Bulguları. Turk J Colorectal Dis 2018; 28: 27-30.
Brenner H, Hoffmeister M, Birkner B, et al. Diagnostic performance of guaiac-based fecal occult blood test in routine screening: state-wide analysis from Bavaria, Germany. Am J Gastroenterol 2014; 109: 427–35.
Sox HC. Office-based testing for fecal occult blood: do only in case of emergency. Ann Intern Med 2005; 142: 479.
Nadel MR, Shapiro JA, Klabunde CN. A national survey of primary care physicians' methods for screening for fecal occult blood. Ann Intern Med 2005; 142: 86-94.
U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 627-37.
Whitlock EP, Lin JS, Liles E. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 638-58.
Kershenbaum A, Flugelman A, Lejbkowicz F, Arad H, Rennert G. Excellent performance of Hemoccult Sensa in organised colorectal cancer screening. Eur J Cancer 2013; 49: 923-30.
van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135: 82–90.
Saito H. Colorectal cancer screening using immunochemical faecal occult blood testing in Japan. J Med Screen 2006; 13: 6–7.
Levi Z, Birkenfeld S, Vilkin A, et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer 2011; 128: 2415-24.

APA	DEMİRAL G, Colakoglu M, AKDOĞAN R, Pergel A (2019). The efficacy of the fecal occult blood test in colorectal cancer screening and evaluation with the literature: Two-year follow-up results of Rize province. , 31 - 37.
Chicago	DEMİRAL GÖKHAN,Colakoglu Muhammet Kadri,AKDOĞAN Remzi Adnan,Pergel Ahmet The efficacy of the fecal occult blood test in colorectal cancer screening and evaluation with the literature: Two-year follow-up results of Rize province. (2019): 31 - 37.
MLA	DEMİRAL GÖKHAN,Colakoglu Muhammet Kadri,AKDOĞAN Remzi Adnan,Pergel Ahmet The efficacy of the fecal occult blood test in colorectal cancer screening and evaluation with the literature: Two-year follow-up results of Rize province. , 2019, ss.31 - 37.
AMA	DEMİRAL G,Colakoglu M,AKDOĞAN R,Pergel A The efficacy of the fecal occult blood test in colorectal cancer screening and evaluation with the literature: Two-year follow-up results of Rize province. . 2019; 31 - 37.
Vancouver	DEMİRAL G,Colakoglu M,AKDOĞAN R,Pergel A The efficacy of the fecal occult blood test in colorectal cancer screening and evaluation with the literature: Two-year follow-up results of Rize province. . 2019; 31 - 37.
IEEE	DEMİRAL G,Colakoglu M,AKDOĞAN R,Pergel A "The efficacy of the fecal occult blood test in colorectal cancer screening and evaluation with the literature: Two-year follow-up results of Rize province." , ss.31 - 37, 2019.
ISNAD	DEMİRAL, GÖKHAN vd. "The efficacy of the fecal occult blood test in colorectal cancer screening and evaluation with the literature: Two-year follow-up results of Rize province". (2019), 31-37.

APA	DEMİRAL G, Colakoglu M, AKDOĞAN R, Pergel A (2019). The efficacy of the fecal occult blood test in colorectal cancer screening and evaluation with the literature: Two-year follow-up results of Rize province. ACTA ONCOLOGICA TURCICA, 52(1), 31 - 37.
Chicago	DEMİRAL GÖKHAN,Colakoglu Muhammet Kadri,AKDOĞAN Remzi Adnan,Pergel Ahmet The efficacy of the fecal occult blood test in colorectal cancer screening and evaluation with the literature: Two-year follow-up results of Rize province. ACTA ONCOLOGICA TURCICA 52, no.1 (2019): 31 - 37.
MLA	DEMİRAL GÖKHAN,Colakoglu Muhammet Kadri,AKDOĞAN Remzi Adnan,Pergel Ahmet The efficacy of the fecal occult blood test in colorectal cancer screening and evaluation with the literature: Two-year follow-up results of Rize province. ACTA ONCOLOGICA TURCICA, vol.52, no.1, 2019, ss.31 - 37.
AMA	DEMİRAL G,Colakoglu M,AKDOĞAN R,Pergel A The efficacy of the fecal occult blood test in colorectal cancer screening and evaluation with the literature: Two-year follow-up results of Rize province. ACTA ONCOLOGICA TURCICA. 2019; 52(1): 31 - 37.
Vancouver	DEMİRAL G,Colakoglu M,AKDOĞAN R,Pergel A The efficacy of the fecal occult blood test in colorectal cancer screening and evaluation with the literature: Two-year follow-up results of Rize province. ACTA ONCOLOGICA TURCICA. 2019; 52(1): 31 - 37.
IEEE	DEMİRAL G,Colakoglu M,AKDOĞAN R,Pergel A "The efficacy of the fecal occult blood test in colorectal cancer screening and evaluation with the literature: Two-year follow-up results of Rize province." ACTA ONCOLOGICA TURCICA, 52, ss.31 - 37, 2019.
ISNAD	DEMİRAL, GÖKHAN vd. "The efficacy of the fecal occult blood test in colorectal cancer screening and evaluation with the literature: Two-year follow-up results of Rize province". ACTA ONCOLOGICA TURCICA 52/1 (2019), 31-37.